Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

L. Gianni, G. Bisagni, M. Colleoni, L. Del Mastro, C. Zamagni, M. Mansutti, M. Zambetti, A. Frassoldati, R. De Fato, P. Valagussa, G. Viale

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences